[go: up one dir, main page]

CA2376675A1 - Antagonistes des voies de signalisation bmp et tgf.beta. - Google Patents

Antagonistes des voies de signalisation bmp et tgf.beta. Download PDF

Info

Publication number
CA2376675A1
CA2376675A1 CA002376675A CA2376675A CA2376675A1 CA 2376675 A1 CA2376675 A1 CA 2376675A1 CA 002376675 A CA002376675 A CA 002376675A CA 2376675 A CA2376675 A CA 2376675A CA 2376675 A1 CA2376675 A1 CA 2376675A1
Authority
CA
Canada
Prior art keywords
smurf
protein
smurf2
cell
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002376675A
Other languages
English (en)
Inventor
Gerald H. Thomsen
Jeffrey Wrana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HSC Research and Development LP
Research Foundation of the State University of New York
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2376675A1 publication Critical patent/CA2376675A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des éléments uniques de la famille Hect des ubiquitine ligases qui ciblent spécifiquement des protéines Smad spécifiques des voies de signalisation BMP et TGF.beta./activine. Les nouvelles ligases ont été appelées Smurf1 et Smurf2. Elles interagissent directement avec les protéines Smad1 et 5 et avec Smad7, respectivement, et régulent l'ubiquitination, le renouvellement et l'activité de protéines Smad et d'autres protéines de ces voies de signalisation. Smurf1 intervient dans les réponses biologiques à BMP, mais pas dans la signalisation d'activine. Dans des embryons d'amphibiens, Smurf1 inhibe les signaux de BMP endogène, ce qui entraîne une formation de motif et une spécification de destin cellulaire modifiées dans le mésoderme et l'ectoderme. La présente invention concerne un lien régulatoire unique entre la voie d'ubiquitination et la régulation de la détermination du destin cellulaire par la superfamille des TGF.beta. au cours du développement embryonnaire. De ce fait, Smurf1 constitue un régulateur négatif de la transduction de signal Smad1 : en ciblant Smad1, Smurf1 bloque la signalisation BMP. Dans des cellules de mammifère, Smurf2 supprime la signalisation TGF.beta., et, chez le xénope, bloque la formation de mésoderme dorsal et provoque une troncature antérieure des embryons. Smurf2 forme un complexe stable avec Smad7, ce qui entraîne une dégradation et une diminution de la signalisation TGF.beta./activine.
CA002376675A 1999-06-11 2000-06-12 Antagonistes des voies de signalisation bmp et tgf.beta. Abandoned CA2376675A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13896999P 1999-06-11 1999-06-11
US60/138,969 1999-06-11
PCT/US2000/016250 WO2000077168A2 (fr) 1999-06-11 2000-06-12 ANTAGONISTES DES VOIES DE SIGNALISATION BMP ET TGF$g(b)

Publications (1)

Publication Number Publication Date
CA2376675A1 true CA2376675A1 (fr) 2000-12-21

Family

ID=22484504

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002376675A Abandoned CA2376675A1 (fr) 1999-06-11 2000-06-12 Antagonistes des voies de signalisation bmp et tgf.beta.

Country Status (7)

Country Link
EP (1) EP1192174A4 (fr)
JP (1) JP2003502064A (fr)
CN (1) CN100379752C (fr)
AU (1) AU782355B2 (fr)
CA (1) CA2376675A1 (fr)
IL (1) IL147005A0 (fr)
WO (1) WO2000077168A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358056B1 (en) 1999-08-30 2008-04-15 Signal Pharmaceuticals Methods for modulating signal transduction mediated by TGF-β and related proteins
WO2003030924A1 (fr) * 2001-10-09 2003-04-17 Osteoscreen, Inc. Identification de modulateurs specifique de la formation osseuse
EP1639008A1 (fr) * 2003-07-01 2006-03-29 VIB vzw Tnf recepteur 2 ubiquitine et ses utilisations
US7901874B2 (en) * 2003-09-11 2011-03-08 Hubit Genomix, Inc. Methods for identifying agents for preventing or treating proliferative diseases, and for inhibiting extracellular matrix or α1 type IV collagen
GB0526664D0 (en) * 2005-11-30 2006-02-08 Plasticell Ltd Method
US8898056B2 (en) 2006-03-01 2014-11-25 Qualcomm Incorporated System and method for generating a separated signal by reordering frequency components
WO2008101951A1 (fr) 2007-02-21 2008-08-28 Vib Vzw Thérapie combinatoire par tnf et alfa-galactosylcéramide
EP2167976A2 (fr) * 2007-05-29 2010-03-31 President And Fellows Of Harvard College Molécules impliquées dans la régulation de l'activité des ostéoblastes et des ostéoclastes, et leurs méthodes d'utilisation
WO2011088163A1 (fr) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Procédés de modulation de remodélisation et structuration squelettiques par modulation de l'activité de shn2, de l'activité de shn3 ou de l'activité combinée de shn2 et de shn3
TWI714528B (zh) * 2014-05-14 2021-01-01 瑞士商諾華公司 甲醯胺衍生物
TW201623288A (zh) * 2014-05-14 2016-07-01 諾華公司 甲醯胺衍生物
KR102360028B1 (ko) * 2014-12-26 2022-02-08 삼성전자주식회사 Smurf2의 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도
CN110196326A (zh) * 2019-06-05 2019-09-03 武汉合研生物医药科技有限公司 一种TGFβR1（T204D）酶活性的快速检测方法及其应用
CN110592032B (zh) * 2019-10-14 2021-04-13 北京理工大学 泛素连接酶Smurf1突变体、编码基因及用途
EP4242318B1 (fr) 2021-01-21 2025-11-12 Cellid Co., Ltd. Nouveau vecteur adénoviral ne comprenant pas d'adénovirus compétent de réplication et utilisation associée
CN117721131A (zh) * 2023-12-19 2024-03-19 吉林大学 一种重组骨形态发生蛋白突变体的制备方法和应用
CN119386159B (zh) * 2024-12-31 2025-04-22 温州医科大学 一种mRNA-多肽复合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001619A (en) * 1995-10-04 1999-12-14 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto
JP2001507239A (ja) * 1997-05-20 2001-06-05 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｓｍａｄ２のリン酸化とｓｍａｄ４との相互作用
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase

Also Published As

Publication number Publication date
EP1192174A4 (fr) 2002-08-28
CN1409722A (zh) 2003-04-09
AU782355B2 (en) 2005-07-21
AU5610700A (en) 2001-01-02
IL147005A0 (en) 2002-08-14
EP1192174A2 (fr) 2002-04-03
WO2000077168A2 (fr) 2000-12-21
CN100379752C (zh) 2008-04-09
WO2000077168A3 (fr) 2001-05-03
JP2003502064A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
AU782355B2 (en) Antagonists of BMP and TGFbeta signalling pathways
US6509152B1 (en) Immunosuppressant target proteins
US6486131B2 (en) Cell-cycle regulatory proteins, and uses related thereto
US6503742B1 (en) Ubiquitin ligases and uses related thereto
WO1995033052A9 (fr) Proteines cibles immunodepressives
US6387640B1 (en) ATM kinase modulation for screening and therapies
US7354722B1 (en) Modulators of Smurf and BMP/TGFβ signaling pathways
US6747128B2 (en) Components of ubiquitin ligase complexes, and uses related thereto
AU2005225080B2 (en) Antagonists of BMP and TGFBeta signalling pathways
US6127158A (en) Ubiquitin conjugating enzymes
US20020088015A1 (en) Wilms' tumor wt1 binding proteins
US20030077288A1 (en) Compositions and methods for treatment of muscle wasting
AU3103899A (en) Identification of factors which mediate the interaction of heterotrimeric g proteins and monomeric g proteins
AU764094B2 (en) MEKK1(serine threonine kinases)-interacting FHA (forkhead associated domain) protein 1 (MIF1)
WO1996040767A2 (fr) Proteines liant e6ap
US20030100489A1 (en) Cell-cycle regulatory proteins, and uses related thereto
WO2001034625A1 (fr) Isolation et caracterisation de proteine humaine nf-e4
US6890733B1 (en) MEKK1 (serine threonine kinases)-interacting FHA (forkhead associated domain) protein 1 (M1F1)
WO1998013494A9 (fr) Proteine fixatrice du gene wt1 suppresseur de la tumeur de wilm
AU8150501A (en) Immunosuppressant target proteins

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20100614